Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 7 of 7 entries
View as:

Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)

Phase: N/A Priority: Normal
NCT ID: NCT04929483 Org: User:
Start: 06/04/21 End: 10/08/24 Due: 10/08/25

PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT05022693 Org: User:
Start: 08/16/21 End: 12/21/21 Due: 12/21/22

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Phase: N/A Priority: Normal
NCT ID: NCT06419374 Org: User:
Start: 05/24/24 End: 08/31/31 Due: 08/31/32

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Phase: N/A Priority: Normal
NCT ID: NCT06318169 Org: User:
Start: 03/13/24 End: 02/28/29 Due: 02/28/30

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

Phase: N/A Priority: Normal
NCT ID: NCT04048135 Org: User:
Start: 07/29/19 End: 01/19/22 Due: 01/19/23

Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia

Phase: N/A Priority: Normal
NCT ID: NCT04541186 Org: User:
Start: 09/01/20 End: 05/31/22 Due: 05/31/23

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

Phase: N/A Priority: Normal
NCT ID: NCT05852431 Org: User:
Start: 06/15/23 End: 09/30/26 Due: 09/30/27